Clinical trials: Myopia, Degenerative
Myopia, Progressive
Management of Myopia in University Students Using Dual Focus Soft Contact Lenses
The purpose of the study is to quantify the effectiveness of Coopervision MiSight contact lenses in slowing the rate of myopia progression in university students.
- Trial name
- MoMUS (NCT05955638)
- Testing
- MiSight contact lenses, Proclear contact lenses
- Where
- 2 sites in United Kingdom
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- University of Bradford
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema
A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV
This is a open label, multicenter, Phase II study to evaluate the usability of the pre-filled syringe (PFS) of SB11 (ranibizumab biosimilar).
- Conditions
- Age-Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema, Central Retinal Vein Occlusion With Macular Edema, Myopic Choroidal Neovascularization
- Trial name
- NCT07550504
- Testing
- SB11 PFS
- Where
- 2 sites in Poland
- Volunteers
- 30 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Diabetic Macular Edema, Age-Related Macular Degeneration
Effect of Corona Virus on Intravitreal Injections
During pandemic of corona virus, patients compliance may be affected. We aim to study the factors lead to unregulated visits and its implications on the final visual outcome.
- Conditions
- Diabetic Macular Edema, Age-Related Macular Degeneration, Choroidal Neovascularization, Myopic Choroidal Neovascularisation
- Trial name
- NCT05494775
- Testing
- Anti-vascular endothelial growth factors (Anti-VEGFs)
- Where
- Egypt
- Volunteers
- 250 people
- Sponsor
- Benha University
Pathological Myopia
Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
This study is designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to…
- Trial name
- NCT01217944
- Testing
- Ranibizumab, Verteporfin PDT
- Where
- 74 sites in Austria, Canada and 18 more
- Volunteers
- 277 people
- Sponsor
- Novartis Pharmaceuticals
Glaucoma, Diabetic Retinopathy (DR)
"My Eyes, My Light": Amar Chokh, Amar Alo
Eye disease affects 2.2 billion people globally, which in turn adversely affects schooling, economic productivity, and participation in social life.
- Conditions
- Glaucoma, Diabetic Retinopathy (DR), Hypertensive Retinopathy, Cataract
- Trial name
- ACA2 (NCT07135570)
- Testing
- Multimodal Screening for Eye Disease, cataract surgery
- Where
- Bangladesh
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Data Yakka, Inc.
Myopia, Progressive Myopia
Atropine Alone vs Atropine Plus Bifocal Spectacles for Myopia Control in Children
Background: Myopia (nearsightedness) is a growing global health concern, projected to affect 50% of the world population by 2050.
- Conditions
- Myopia, Progressive Myopia, Refractive Errors
- Trial name
- COMBAT-Myopia (NCT07614113)
- Testing
- Atropine Sulfate 0.05% Ophthalmic Solution, Bifocal Spectacles
- Where
- Pakistan
- Volunteers
- 210 people
- Sponsor
- University of Faisalabad
Myopia, Progressive
DIMS-myopia Progression ADN Axial Length Growth
To confirm the efficacy of DIMS lenses in controlling myopia progression, we planned a prospective randomized controlled clinical study.
- Trial name
- NCT05300321
- Testing
- frame lens
- Where
- China
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Tianjin Eye Hospital
Myopia, Progressive
Effect of Atropine on Pupil Size and Quality of Vision
This aims to investigated the short-term (12, 16, and 20 h) effects of 0.01% atropine (0.1 mg/ml) on pupil size and subjective quality of vision in participants with myopia.
- Trial name
- NCT06071260
- Testing
- 0.01% atropine eye drop
- Where
- China
- Volunteers
- 40 people
- Sponsor
- He Eye Hospital
Macular Degeneration, Age Related, Myopic Choroidal Neovascularisation
VISUPRIME® Eye Drops
The study purpose is to assess the efficacy of VISUPRIME® eye drops in preventing the conjunctival bacterial load in patients undergoing to anti-VEGF injection.
- Conditions
- Macular Degeneration, Age Related, Myopic Choroidal Neovascularisation, Proliferative Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT05677685
- Testing
- VISUPRIME
- Where
- 6 sites in Italy
- Volunteers
- 78 people
- Sponsor
- VISUfarma SpA
Myopia, Progressive
Myopia Progression With Freeform Myopia Control Spectacles
This is a prospective, randomized clinical trial. There will be a total of 180 participants randomized into three groups, Group 1 - 60 participants will wear the commercial peripheral plus myopia control lens (CML).
- Trial name
- NCT06927388
- Testing
- freeform myopia control spectacles, Commercial myopia control spectacle lens (CML)
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Shanghai Eye Disease Prevention and Treatment Center
Diabetic Retinopathy (DR), Retinal Vein Occlusion (RVO)
High-throughput Large-model-based AI-assisted Diagnosis Using OCT
This observational study aims to establish key technologies for high-throughput, large-model-based AI-assisted diagnosis using optical coherence tomography (OCT) and OCT angiography (OCTA).
- Conditions
- Diabetic Retinopathy (DR), Retinal Vein Occlusion (RVO), Age-Related Macular Degeneration (AMD), Pathologic Myopia
- Trial name
- NCT07249307
- Testing
- No intervention
- Volunteers
- 2,000 people
- Sponsor
- Peking Union Medical College Hospital
Myopia, Progressive
Study of OT-101 in Treating Myopia
This is a phase III, randomized, double-masked, placebo-controlled, parallel-group, multicenter safety, tolerability, and efficacy study of atropine sulfate 0.01% (OT-101) as an investigational treatment for myopia in pediatric…
- Trial name
- NCT04770610
- Testing
- OT-101 Ophthalmic Solution, Vehicle
- Where
- 15 sites in United States
- Volunteers
- 678 people
- Sponsor
- Ocumension (Hong Kong) Limited
Myopia, Progressive
Slow Myopia Progression With Different Irradiance Light
It is a prospective clinical control study on red light control myopia with specail design spectacles for 75 children in 3 groups. Study Groups with two different powers of 0.6 mW and 1.2 mW at wavelength of 650nm.
- Trial name
- NCT05881655
- Testing
- Airdoc Red Lighting Device, Special Spectacles to Control Myopia
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Beijing Airdoc Technology Co., Ltd.
no Obvious Abnormalities, Diabetic Retinopathy (DR)
Retinal Clinical Assessment With AI-derived Quantitative Information
This randomized controlled trial evaluates whether providing clinicians with AI-derived quantitative retinal information improves the quality and efficiency of retinal clinical assessment.
- Conditions
- no Obvious Abnormalities, Diabetic Retinopathy (DR), AMD, Cup-to-disc Ratio Bigger Than 0.5
- Trial name
- NCT07291960
- Testing
- AI-derived retinal quantitative information-assisted reporting
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Beijing Tongren Hospital
Myopia Progression, Atropine
Efficacy and Safety of 0.01%, 0.03%, and 0.05% Atropine Eye Drops in Reducing Myopia Progression
Myopia is one of the fastest-growing ocular disorders worldwide and has become a major public health concern, especially among children and adolescents.
- Trial name
- NCT07626892
- Testing
- Atropine sulphate eye drop 0.01%, Atropine sulphate eye drop 0.03%, Atropine sulphate eye drop 0.05%
- Where
- Pakistan
- Volunteers
- 95 people
- Sponsor
- Khyber Medical College, Peshawar
Choroidal Neovascularization, Age Related Macular Degeneration
SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia
This investigator initiated pilot study is designed to investigate the efficacy and safety of SD-OCT-guided intravitreal ranibizumab treatment in choroidal neovascularization (CNV) due to myopia.
- Trial name
- NCT03409250
- Testing
- Ranibizumab, Lucentis
- Where
- Switzerland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vista Klinik
Punctate Inner Choroidopathy
PIC and Its Role in Progression of Pathological Myopia
Aim of the work PIC in pathological myopia has not been well documented due to difficult in diagnosis we conducted this retrospective study to characterize the clinical features of PIC in high myopic eye.
- Trial name
- NCT04561869
- Where
- Japan
- Volunteers
- 39 people
- Sponsor
- Assiut University
Myopia, Progressive
Myopia Control Combined PBM With Myopic Defocus Lens in Children
To study the efficacy of myopi control with two methods: low lever red light and peripheral defocus spectacles with four groups and design with prospective, double-blind, randimized, and with control for 6 month.
- Trial name
- NCT05756959
- Testing
- PBM, Peripheral defocus spectacles, Single vision spectacles
- Where
- China
- Volunteers
- 304 people
- Sponsor
- Beijing Airdoc Technology Co., Ltd.
Myopia, Progressive
Differences and Wearing Safety and Comfort of New Defocus Incorporated Multiple Segments Spectacle Lenses
To evaluate the differences in controlling the progression of myopia in adolescents and the safety and comfort of wearing different types of defocus incorporated multiple segments spectacle lenses, to explore the feasibility of…
- Trial name
- NCT06221592
- Testing
- defocus spectacle lenses
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Shanghai Eye Disease Prevention and Treatment Center
Myopia, Progressive
Clinical Study of Light Therapy to Control Myopia Progression in Children
Low-lever red light therapy (LLLT) has been used to control myopia progression in China for a few years besides amblyopia therapy for a few decades.
- Trial name
- NCT05761379
- Testing
- Photobiomodualtion Therapy, Single vision spectacles for correction myopia
- Where
- China
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Beijing Airdoc Technology Co., Ltd.